AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21320721 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 PGF (25 mg dinoprost) at CIDR removal on Day 5
Number of subjects: 562
Study 21320721 — intervention group
Group type: COMPARATOR
Intervention: 2 PGF (two doses of 25 mg dinoprost, first dose at CIDR removal on Day 5, second dose 6 h later)
Number of subjects: 562
Study 19335072 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy with scaling/root planing and oral hygiene instructions
Number of subjects: 40
Study 19335072 — intervention group
Group type: COMPARATOR
Intervention: No periodontal therapy
Number of subjects: 40
Study 19335072 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha therapy
Number of subjects: 40
Study 19335072 — intervention group
Group type: COMPARATOR
Intervention: No anti-TNF-alpha therapy
Number of subjects: 40
Study 17766607 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental drainage of fetal blood
Number of subjects: 86
Study 17766607 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 86
Study 15167607 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion cyclosporine (CSA)
Number of subjects: 22
Study 15167607 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC)
Number of subjects: 22
Study 11474638 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH therapy for 6-12 months
Number of subjects: 0
Study 11474638 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 11474638 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acromegaly patients
Number of subjects: 0
Study 9701130 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐component acellular pertussis vaccine
Number of subjects: 669
Study 9701130 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐component acellular pertussis vaccine
Number of subjects: 669
Study 9701130 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐cell pertussis vaccine
Number of subjects: 669
Study 9701130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diphtheria and tetanus toxoids)
Number of subjects: 669
Study 9701130 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with proven pertussis
Number of subjects: 669
Study 7958670 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin-17 (15, 30, and 60 pmol.kg-1.h-1)
Number of subjects: 8
Study 7958670 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 (15 pmol.kg-1.h-1)
Number of subjects: 8
Study 7958670 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 (higher infusion rates)
Number of subjects: 8
Study 7958670 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 plus lox
Number of subjects: 8
Study 7958670 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 together with gastrin-17
Number of subjects: 8
Study 7958670 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-stimulated plasma gastrin concentrations
Number of subjects: 8
Study 7958670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham feeding-induced acid secretion during lox infusion
Number of subjects: 8
Study 3117554 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerin (2.5 mg in 49% and 5.0 mg in 51%)
Number of subjects: 126
Study 3117554 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nitroglycerin
Number of subjects: 126
Study 3117554 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerin
Number of subjects: 126
Study 29929682 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-facilitated 5A's intervention
Number of subjects: 221
Study 29929682 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 221
Study 27113188 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reconstruction of lung cancer using Mimics software on a personal computer
Number of subjects: 24
Study 27113188 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical scheme
Number of subjects: 24
Study 25111351 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (20 U)
Number of subjects: 547
Study 25111351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 22768661 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol with 400 mg of elemental calcium daily for 12 months
Number of subjects: 20
Study 22768661 — intervention group
Group type: COMPARATOR
Intervention: Menatetrenone with 400 mg of elemental calcium daily for 12 months
Number of subjects: 20
Study 20547822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided TAP blocks (2 x 20 mL 0.5% ropivacaine)
Number of subjects: 65
Study 20547822 — intervention group
Group type: COMPARATOR
Intervention: Multimodal IV analgesia with placebo (0.9% saline)
Number of subjects: 65
Study 17984215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 813
Study 17984215 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment alone
Number of subjects: 813
Study 15973773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterysium glucosides for three months with prednisone
Number of subjects: 80
Study 15973773 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) by intermission intravenous pulse with prednisone
Number of subjects: 80
Study 11841992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GLP-1
Number of subjects: 0
Study 11841992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10028936 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 30
Study 10028936 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25-50 mg twice daily)
Number of subjects: 30
Study 10829886 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin for 7 days
Number of subjects: 40
Study 10829886 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 40
Study 1439313 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine treatment (followed 2‐162 months)
Number of subjects: 20
Study 1439313 — intervention group
Group type: COMPARATOR
Intervention: Thyroidectomy (followed 2‐158 months)
Number of subjects: 20
Study 3026005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin alone
Number of subjects: 41
Study 3026005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin plus gentamicin
Number of subjects: 41
Study 3026005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin alone
Number of subjects: 41
Study 3026005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamicin
Number of subjects: 41
Study 29757845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute care nurse practitioner (ACNP) presence during daily ICU multidisciplinary rounds
Number of subjects: 81
Study 29757845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACNP presence during rounds)
Number of subjects: 81
Study 27487253 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG‐adjusted enoxaparin dosing (35 mg twice daily)
Number of subjects: 185
Study 27487253 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (30 mg twice daily)
Number of subjects: 185
Study 25527750 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (21 g/d)
Number of subjects: 21
Study 25527750 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble corn fiber (SCF; 21 g/d)
Number of subjects: 21
Study 25527750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber supplementation (polydextrose and SCF combined)
Number of subjects: 21
Study 25527750 — intervention group
Group type: COMPARATOR
Intervention: NFC (no supplemental fiber)
Number of subjects: 21
Study 23717826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain vigilance
Number of subjects: 40
Study 23717826 — intervention group
Group type: COMPARATOR
Intervention: Pain catastrophizing and fear of pain
Number of subjects: 40
Study 21204914 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 12
Study 21204914 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple juice
Number of subjects: 12
Study 21204914 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 18057215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment in patients with CKD
Number of subjects: 5154
Study 18057215 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in patients with CKD
Number of subjects: 5154
Study 18057215 — intervention group
Group type: COMPARATOR
Intervention: Patients without CKD
Number of subjects: 5154
Study 16688995 — intervention group
Group type: EXPERIMENTAL
Intervention: Shexiang Injection (SI) plus conventional therapy
Number of subjects: 42
Study 16688995 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control group)
Number of subjects: 42
Study 12702115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in smokers
Number of subjects: 31
Study 12702115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in non-smokers
Number of subjects: 31
Study 12702115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in non-smokers (proximal furcation defects)
Number of subjects: 31
Study 12702115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in smokers (proximal furcation defects)
Number of subjects: 31
Study 12702115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in non-smokers (facial/lingual defects)
Number of subjects: 31
Study 12702115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in smokers (facial/lingual defects)
Number of subjects: 31
Study 12702115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in non-smokers (proximal defects)
Number of subjects: 31
Study 12702115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in smokers (proximal defects)
Number of subjects: 31
Study 10750647 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (50 mg/m2 every 4 weeks) + Tamoxifen (30 mg bid)
Number of subjects: 32
Study 10750647 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (30 mg bid)
Number of subjects: 32
Study 7475043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 7475043 — intervention group
Group type: EXPERIMENTAL
Intervention: Almokalant Cpl 20
Number of subjects: 87
Study 7475043 — intervention group
Group type: EXPERIMENTAL
Intervention: Almokalant Cpl 50
Number of subjects: 87
Study 7475043 — intervention group
Group type: EXPERIMENTAL
Intervention: Almokalant Cpl 100
Number of subjects: 87
Study 7475043 — intervention group
Group type: EXPERIMENTAL
Intervention: Almokalant Cpl 150
Number of subjects: 87
Study 2125857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (30 mg daily p.o.)
Number of subjects: 36
Study 2125857 — intervention group
Group type: COMPARATOR
Intervention: Orphenadrine (150 mg daily p.o.)
Number of subjects: 36
Study 2125857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7032224 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting neuroleptics (fluphenazine decanoate or flupenthixol decanoate)
Number of subjects: 41
Study 7032224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31083802 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy for hepatitis C
Number of subjects: 334
Study 31083802 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy for hepatitis C in cirrhotic patients
Number of subjects: 334
Study 31083802 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy for hepatitis C in non-cirrhotic patients
Number of subjects: 334
Study 31083802 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy for hepatitis C in patients without end-of-treatment response (EoTR)
Number of subjects: 334
Study 28771524 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief case management
Number of subjects: 166
Study 28771524 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study 26154029 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 0.2 g/L 2'FL
Number of subjects: 254
Study 26154029 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 1.0 g/L 2'FL
Number of subjects: 254
Study 26154029 — intervention group
Group type: COMPARATOR
Intervention: Formula with 64.3 kcal/dL (control group)
Number of subjects: 254
Study 26154029 — intervention group
Group type: COMPARATOR
Intervention: HM-fed infants (control group)
Number of subjects: 254
Study 26154029 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulas (including those with 2'FL)
Number of subjects: 254
Study 26154029 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'FL supplementation
Number of subjects: 254
Study 24191398 — intervention group
Group type: EXPERIMENTAL
Intervention: PIR
Number of subjects: 320
Study 24191398 — intervention group
Group type: COMPARATOR
Intervention: PIR-taping
Number of subjects: 320
Study 21638277 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 280
Study 21638277 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 280
Study 20001837 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sensory integration therapy with Thai Traditional Massage (TTM)
Number of subjects: 60
Study 20001837 — intervention group
Group type: COMPARATOR
Intervention: Standard sensory integration therapy (SI)
Number of subjects: 60
Study 20001837 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sensory integration therapy with TTM
Number of subjects: 60
Study 16282579 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 18
Study 16282579 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 18
Study 16282579 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 18
Study 15478167 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 7
Study 15478167 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 7
Study 10997428 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg inhalation
Number of subjects: 22
Study 10997428 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dependent zones of the lung
Number of subjects: 22
Study 10997428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator response assessment
Number of subjects: 22
Study 9062615 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 58
Study 9062615 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia
Number of subjects: 58
Study 9062615 — intervention group
Group type: COMPARATOR
Intervention: Control group with antegrade cardioplegia
Number of subjects: 58
Study 9062615 — intervention group
Group type: COMPARATOR
Intervention: Control group with retrograde cardioplegia
Number of subjects: 58
Study 9062615 — intervention group
Group type: EXPERIMENTAL
Intervention: RCA-ante group
Number of subjects: 58
Study 9062615 — intervention group
Group type: EXPERIMENTAL
Intervention: RCA-retro group
Number of subjects: 58
Study 9062615 — intervention group
Group type: COMPARATOR
Intervention: C-ante group
Number of subjects: 58
Study 9062615 — intervention group
Group type: COMPARATOR
Intervention: C-retro group
Number of subjects: 58
Study 8202769 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 83
Study 8202769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 3297810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/day
Number of subjects: 16
Study 3297810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (p)
Number of subjects: 16
Study 29273206 — intervention group
Group type: EXPERIMENTAL
Intervention: Top group of CVH score (≥10 points)
Number of subjects: 200
Study 26456812 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (primary treatment for ovarian cancer)
Number of subjects: 231
Study 23456327 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to spoken words with vowel harmony in the voice of a single talker.
Number of subjects: 0
Study 23456327 — intervention group
Group type: COMPARATOR
Intervention: Familiar talker accent
Number of subjects: 0
Study 23456327 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar talker accent
Number of subjects: 0
Study 20624273 — intervention group
Group type: EXPERIMENTAL
Intervention: Optilene Mesh Elastic
Number of subjects: 80
Study 20624273 — intervention group
Group type: COMPARATOR
Intervention: Ultrapro Mesh
Number of subjects: 80
Study 18445839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetically guided FU dose adjustment (arm B)
Number of subjects: 208
Study 18445839 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing of fluorouracil (arm A)
Number of subjects: 208
Study 16766630 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular genetics approaches
Number of subjects: 0
Study 12727395 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention to promote exclusive breastfeeding
Number of subjects: 1115
Study 11032209 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid administered during the first 48 hours (mean=5824 mL)
Number of subjects: 125
Study 11032209 — intervention group
Group type: EXPERIMENTAL
Intervention: BUN level (mean=34)
Number of subjects: 125
Study 11032209 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (mean=59 years)
Number of subjects: 125
Study 8773160 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 975 mg qid for 4 days
Number of subjects: 16
Study 8773160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg qid for 4 days
Number of subjects: 16
Study 8773160 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide 5 mg plus GTT
Number of subjects: 16
Study 8773160 — intervention group
Group type: COMPARATOR
Intervention: Baseline oral glucose tolerance test (GTT)
Number of subjects: 16
Study 1553404 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature biofeedback-assisted relaxation
Number of subjects: 19
Study 1553404 — intervention group
Group type: COMPARATOR
Intervention: Attention control, 'stress education'
Number of subjects: 19
Study 3883729 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (37.5 to 75 mg daily)
Number of subjects: 14
Study 3883729 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60 to 120 mg daily)
Number of subjects: 14
Study 3883729 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14
Study 3883729 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14
Study 30843623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoplasty
Number of subjects: 0
Study 30843623 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty
Number of subjects: 0
Study 30843623 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 30165520 — intervention group
Group type: EXPERIMENTAL
Intervention: Unchanged LT4 dose
Number of subjects: 138
Study 30165520 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher LT4 dose
Number of subjects: 138
Study 30165520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower LT4 dose
Number of subjects: 138
Study 30165520 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 138
Study 30165520 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived higher LT4 doses
Number of subjects: 138
Study 30165520 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusting LT4 doses
Number of subjects: 138
Study 27424010 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (2.4 g/day for 8 weeks)
Number of subjects: 72
Study 27424010 — intervention group
Group type: COMPARATOR
Intervention: Placebo (paraffin)
Number of subjects: 72
Study 24861034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronase premedication
Number of subjects: 0
Study 24861034 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI) endoscopy with pronase premedication
Number of subjects: 0
Study 24861034 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pronase premedication)
Number of subjects: 0
Study 22397629 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 vaccination
Number of subjects: 4405
Study 19149498 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcarnosine eye drops
Number of subjects: 0
Study 19149498 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcarnosine-laden therapeutic contact lenses
Number of subjects: 0
Study 17461355 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy for oropharyngeal dysphagia (specific therapeutic programs not sufficiently described)
Number of subjects: 0
Study 17461355 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing training
Number of subjects: 0
Study 17461355 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-language intervention
Number of subjects: 0
Study 15304592 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg/day
Number of subjects: 60
Study 15304592 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/day
Number of subjects: 60
Study 15304592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12527501 — intervention group
Group type: EXPERIMENTAL
Intervention: Total edentulous
Number of subjects: 274
Study 12527501 — intervention group
Group type: EXPERIMENTAL
Intervention: Edentulous in one jaw
Number of subjects: 274
Study 12527501 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 274
Study 12527501 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining sound teeth, decayed teeth, radices relictae
Number of subjects: 274
Study 9583547 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral administration of bupivacaine
Number of subjects: 12
Study 9583547 — intervention group
Group type: COMPARATOR
Intervention: Interpleural administration of bupivacaine
Number of subjects: 12
Study 9583547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Paravertebral and Interpleural)
Number of subjects: 12
Study 8608752 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-bit color images
Number of subjects: 11